Brief: Celyad Oncology Announces Clinical Hold Of CYAD-101-002 Phase 1b Trial

Celyad Oncology SA

02/03/2022 13:16

March 2 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * CELYAD ONCOLOGY ANNOUNCES CLINICAL HOLD OF CYAD-101-002
PHASE 1B
TRIAL
    * FDA PLACED CYAD-101-002 (KEYNOTE-B79) PHASE 1B TRIAL ON
CLINICAL
HOLD DUE TO INSUFFICIENT INFORMATION TO ASSESS RISK TO STUDY
SUBJECTS
    * COMPANY PREVIOUSLY VOLUNTARILY PAUSED CYAD-101-002 TRIAL
TO
INVESTIGATE REPORTS OF TWO FATALITIES IN STUDY

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX6KD0nd
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))